ABIVAX to participate in RBC Capital Markets Global Healthcare Conference on February 22-23, 2017 in New York City

Paris, February 16th, 2017 at 6:00pm (CET) – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral diseases, announced today that members of the management team will participate at the 2017 RBC Capital Markets Global Healthcare Conference to be held on February 22-23 at the New York Palace in New York City.

Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX is scheduled to participate in a fireside chat with an RBCCM healthcare analyst at 1:35 PM (EST) on February 22nd. Additionally, Prof. Ehrlich, along with ABIVAX’s CFO and CMO, Didier Blondel and Jean-Marc Steens, M.D., will be available for one-on-one meetings with interested investors over the course of the conference.                        

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41